Archive / Blog

RSS feed for this section

Dr. Michael Har-Noy Describes The Potential Value Of AlloStimTM Infusion In HIV-Infected Patients

Dr. Michael Har-Noy, founder of the Israeli biotechnology company Immunovative Therapies, Ltd., indicates that HIV infection results in significant loss of the production of interferon.  Gamma interferon is a cytokine that is produced primarily from Th1 helper cells.  Gamma interferon is crucial for the suppression of viral replication.  Dr. Michael Har-Noy says that in cancer […]

Dr. Michael Har-Noy Introduces the “Mirror EffectTM” – A Unique Approach to Treating Cancer

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., describes the “Mirror EffectTM” as an immune mechanism that solves the problem of separating the curative graft versus tumor (GVT) effect of bone marrow transplant (BMT) procedures from the lethal graft versus host disease (GVHD) complication. Dr. Michael Har-Noy says the solution was to create […]

Phase I/II Trial of AlloStim

Concept of Mirror Effect                 Breakdown of Study Patients   Outcome Data For Patients                 Adverse Effects of AlloStim vs. Drugs on Market

Published Abstract Detailing Amazing, Unprecedented Response of HER2+ Breast Cancer Patients To AlloStim

Response of HER2+ breast cancer patients to allogeneic cell immunotherapy. Meeting:  2012 ASCO Annual Meeting Abstract Number:  e13013 Citation:  J Clin Oncol 30, 2012 (suppl; abstr e13013)   Author(s):  Michael Har-Noy, Wirote Lausoontornsiri, Reuven Or, Emmanual Katsanis; Immunovative Therapies, Ltd, Jerusalem, Israel; Clinical Cancer Research Department, National Cancer Institute of Thailand, Bangkok, Thailand; Hadassah Hebrew […]

Peer-Reviewed Publications by Michael Har-Noy Ph.D.

For the official Immunovative Therapies, Ltd. corporate website, please visit Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with utologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, Olver CS, Lencioni AM, Dusto NL, Tal A, Michael Har-Noy,* Lillehei KO, Katsanis E, […]